The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 07, 2023
Filed:
May. 30, 2018
Bristol-myers Squibb Company, Princeton, NJ (US);
James Novotny, Jr., Milford, NJ (US);
Nils Lonberg, Woodside, CA (US);
Cyrus Hedvat, New York, NY (US);
Raphael Clynes, West Nyack, NY (US);
Darren Locke, Bordentown, NJ (US);
John P. Cogswell, Yardley, PA (US);
Jeffrey Jackson, Schwenksville, PA (US);
Christopher Harbison, Hamilton, NJ (US);
Robin Edwards, Newtown, PA (US);
Bristol-Myers Squibb Company, Princeton, NJ (US);
Abstract
The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.